The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
September 30, 2024
View Complete Issue         Table of Contents 2019 
Betibeglogene Autotemcel (Zynteglo) for Beta Thalassemia (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Betibeglogene Autotemcel (Zynteglo) for Beta Thalassemia (online only)
September 30, 2024 (Issue: 1712)
Betibeglogene autotemcel (Zynteglo — Bluebird Bio), an autologous lentiviral vector cell-based gene therapy, has been approved by the FDA for one-time treatment of transfusion-dependent beta thalassemia in children and adults. Exagamglogene...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Betibeglogene Autotemcel (Zynteglo) for Beta Thalassemia (online only)
Article code: 1712c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.